Nitric oxide as a target for dietary intervention in colitis
Nitric oxide as a target for dietary intervention in colitis
批准号:
7674956
负责人:
MICHAEL WARGOVICH
金额:
$14.96万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-01 至 2010-04-30
关键词:
AbateAdverse effectsAlternative MedicineAmericanAnimal ExperimentationAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsCellsChronicClinical TrialsCoculture TechniquesColitisColon CarcinomaColorectalColorectal CancerComplementDNADNA DamageDevelopmentDietary InterventionDiseaseDisease remissionEventFree RadicalsFutureGinkgo bilobaGinseng PreparationGoalsHandHumanImmunosuppressive AgentsIn VitroInflammationInflammatoryInterventionMediatingMedicalMolecularMusNitric OxideNitric Oxide SynthaseOrthomolecular TherapyPanaxPanax ginsengPathologyPathway interactionsPatientsPrincipal InvestigatorProductionProteinsPublishingReagentRefractoryResearch DesignRodent ModelSourceSymptomsSystemTherapeutic AgentsUlcerative ColitisUnited StatesWorkcancer cellcancer riskcarcinogenesiscell typedietary supplementshuman NOS2A proteinillness lengthin vivomacrophagemouse modelnovel therapeuticspre-clinicalprogramsstem
中文摘要
描述(由申请人提供):目前对结肠炎的医学干预包括应用抗炎和/或免疫抑制剂,每种药物都有不良副作用的发展。尽管有多种治疗方案,但对许多患者来说,疾病仍然是难治性的,有间歇性的缓解期。显然,需要新的治疗策略来减轻结肠炎的影响和后遗症。替代药物的使用在美国很常见,目前40%的结肠炎患者使用膳食补充剂。然而,使用替代药物的科学证据往往缺乏或薄弱,并且尚未严格评估潜在的有益作用机制。诱导型一氧化氮合酶(iNOS)过量产生一氧化氮已被认为是结肠炎的致病因素之一。在这里,我们假设两种抗氧化草药补充剂银杏叶和西洋参(Panax quinquefolis)将通过抑制一氧化氮合酶来抑制结肠炎,抑制随后的一氧化氮产生,从而调节一氧化氮诱导的DNA损伤。尽管已发表的研究表明,银杏和人参都能抑制各种细胞类型中一氧化氮的产生,但它们对人类结直肠细胞的影响尚未得到研究。该项目的目的是确定银杏和人参调节一氧化氮产生和一氧化氮诱导人类结肠癌细胞DNA损伤的作用和机制。我们还将通过使用iNOS-/-和iNOS+/+诱导结肠炎的小鼠来确定银杏或人参是否能减少结肠炎,并检查这是否是一氧化氮介导的事件。除了病理学检查结肠炎的程度外,我们还将通过检查银杏和人参对炎症驱动的DNA损伤的影响来扩展体外研究结果。由于pRb过度磷酸化与癌变有关,并且在结肠炎中过度磷酸化,我们将研究银杏和人参对pRb过度磷酸化的影响。这些研究应该为银杏和人参通过明确的分子途径改善实验性结肠炎的潜在应用提供强有力的临床前证据。这个应用程序的总体目标是为公众提供一些保证,膳食补充剂银杏和人参,有能力减轻结肠炎。
英文摘要
DESCRIPTION (provided by applicant): Current medical interventions for colitis consist of application of anti-inflammatory and/or immunosuppressive agents, each complicated by the development of undesirable side effects. Despite treatment options, for many patients disease remains refractory with episodic periods of remission. Clearly, novel therapeutic strategies are needed to lessen the impact and sequelae of colitis. Use of alternative medicine is common in the United States and 40% of colitis suffers currently use dietary supplements. However, the scientific evidence for the use of alternative medicines is often lacking or weak, and potentially beneficial mechanisms of action have not rigorously been assessed. Overproduction of nitric oxide by inducible nitric oxide synthase (iNOS) has been proposed as a pathogenic factor in colitis. Here, we postulate that two antioxidant herbal supplements, Ginkgo biloba and American ginseng (Panax quinquefolis), will inhibit colitis through the inhibition of nitric oxide synthase, inhibiting subsequent nitric oxide production, and thus modulate nitric oxide-induced DNA damage. Although published studies have shown ginkgo and ginseng both inhibit nitric oxide production in various cell types, their effects in human colorectal cells have not been studied. An objective of this project is to determine the effects and mechanisms by which ginkgo and ginseng modulate nitric oxide production and nitric oxide induced DNA damage in human colon cancer cells. We will also determine whether ginkgo or ginseng reduce colitis and examine whether this is a nitric oxide- mediated event by using iNOS-/- and iNOS+/+ mice with induced colitis. In addition to pathology to examine the extent of colitis, we will extend in vitro findings by examining the effects of ginkgo and ginseng on inflammation-driven DNA damage. Because pRb hyperphosphorylation is associated with carcinogenesis and it is hyperphosphorylated in colitis, we will examine the effects of ginkgo and ginseng on pRb hyperphosphorylation. These studies should provide strong pre-clinical evidence for the potential use of ginkgo and ginseng in the amelioration of experimental colitis through defined molecular pathways. The overall goal of this application is to provide the public some assurance that the dietary supplements gingko and ginseng, have the capacity to alleviate colitis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer Prevention by West African Medicinal Plants
-
批准号:7037282
-
项目类别:
-
资助金额:$15.37万
-
财政年份:2006
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Nitric oxide as a target for dietary intervention in colitis
-
批准号:7244097
-
项目类别:
-
资助金额:$2.28万
-
财政年份:2006
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Nitric oxide as a target for dietary intervention in colitis
-
批准号:7091092
-
项目类别:
-
资助金额:$21.3万
-
财政年份:2006
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Cancer Prevention by West African Medicinal Plants
-
批准号:7625387
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2006
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:6923949
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:6507756
-
项目类别:
-
资助金额:$25.81万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:8271427
-
项目类别:
-
资助金额:$25.62万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:8686707
-
项目类别:
-
资助金额:$25.18万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:8636106
-
项目类别:
-
资助金额:$24.4万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:7905557
-
项目类别:
-
资助金额:$26.41万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:6603800
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:6757163
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:8101884
-
项目类别:
-
资助金额:$25.62万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
Tea Modulation of Colon Carcinogenesis
-
批准号:7073500
-
项目类别:
-
资助金额:$25.29万
-
财政年份:2002
-
负责人:MICHAEL WARGOVICH
-
依托单位:
PPAR GAMMA AGONISTS FOR THE PREVENTION OF COLON CANCER
-
批准号:6287644
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2001
-
负责人:MICHAEL WARGOVICH
-
依托单位:
PPAR GAMMA AGONISTS FOR THE PREVENTION OF COLON CANCER
-
批准号:6489435
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2001
-
负责人:MICHAEL WARGOVICH
-
依托单位:
CALCIUM AND ASPIRIN PREVENTION TRIAL
-
批准号:2468706
-
项目类别:
-
资助金额:$2.18万
-
财政年份:1995
-
负责人:MICHAEL WARGOVICH
-
依托单位:
EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS
-
批准号:2540015
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1995
-
负责人:MICHAEL WARGOVICH
-
依托单位:
EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS
-
批准号:2748291
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1995
-
负责人:MICHAEL WARGOVICH
-
依托单位:
CALCIUM AND ASPIRIN PREVENTION TRIAL
-
批准号:2106408
-
项目类别:
-
资助金额:$28.54万
-
财政年份:1995
-
负责人:MICHAEL WARGOVICH
-
依托单位:
海外基金